FindTrial
Sign In

Optimization and promotion of treatment for recurrent nasopharyngeal carcinoma

Optimization and promotion of treatment for recurrent nasopharyngeal carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800018123
Enrollment
Unknown
Registered
2018-08-31
Start date
2018-10-30
Completion date
Unknown
Last updated
2018-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nasopharyngeal carcinoma

Interventions

Group 1:surgery
Group 2:Radiotherapy

Sponsors

Eye, Ear ,Nose and Throat Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) pathology confirmed the recurrence of nasopharyngeal carcinoma after radical radiotherapy; (2) patients with residual nasopharyngeal carcinoma after radical radiotherapy; (3) radiotherapy is not sensitive to nasopharyngeal malignant tumor.

Exclusion criteria

Exclusion criteria: 1. patients with primary nasopharyngeal carcinoma; 2. recurrence of nasopharyngeal carcinoma with distant metastasis. 3. Halfway for any reason to decide to quit. 4. Refusing to accept surgical treatment; 5. patients who are unable to tolerate treatment because of poor overall condition.

Design outcomes

Primary

MeasureTime frame
survival;—

Countries

China

Contacts

Public ContactWANG DEHUI

Eye, Ear, Nose and Throat Hospital, Fudan University

wangdehuient@sina.com+86 13701852008

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026